



## Codexis Appoints Scott Watson as Vice President of Sales and Marketing

June 4, 2013

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 4, 2013-- Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced the appointment of Scott Watson as Vice President of Sales and Marketing, effective May 2013. Mr. Watson has more than 25 years of experience in sales, marketing and business development, including in the pharmaceutical and fine chemicals markets.

"Scott brings a strong track record of success to Codexis, along with a wealth of knowledge and connections from his various roles in the pharmaceutical and fine chemical industries," said John Nicols, President and CEO of Codexis. "We continue to expand our pharmaceutical business through new collaborations with strategic partners, and this hire will allow us to capitalize on the many opportunities within both the pharmaceutical industry and other complex chemistry markets where our tailored enzymes can provide significant benefits for our customers."

"Codexis is the world leader in developing biocatalysts for the pharmaceutical industry and I am very excited to be joining the team at this time," said Scott Watson. "The opportunities in the pharmaceutical market continue to grow, and I look forward to helping Codexis further expand its presence, in pharmaceutical and other complex chemistry markets, during the coming years."

Before joining Codexis, Mr. Watson served most recently as the Executive Director of Sales and Marketing at AMPAC Fine Chemicals, a leading manufacturer of custom small molecule active pharmaceutical ingredients. From 2008 to 2009, Mr. Watson served as Vice President of Sales and Marketing for Girindus, a diverse service company to the pharmaceutical industry, where he was responsible for realigning the company's sales strategy. Prior to Girindus, Mr. Watson held sales positions of growing responsibility with various companies, including Aptuit, DSM and Eastman Chemical Company.

Mr. Watson is a former officer in the U.S. Navy and holds a B.S. in Chemistry from the U.S. Naval Academy and an M.B.A. in Finance and Marketing from George Mason University.

### About Codexis, Inc.

Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical production. Codexis' proven technology enables scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development – from research to manufacturing. For more information, see [www.codexis.com](http://www.codexis.com).

### Forward-Looking Statements

This press release contains forward-looking statements relating to the expansion of Codexis' pharmaceutical business, Codexis' abilities to capitalize on business opportunities in the pharmaceutical and other markets and the benefits that Codexis' enzymes can provide its customers. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis' control and that could materially affect actual results. Factors that could materially affect actual results include Codexis' dependence on a limited number of customers and a limited number of products in its pharmaceutical business, Codexis' abilities to develop and commercialize new products for the pharmaceutical market, Codexis' dependence on its collaborators and the successful management of these relationships in developing and commercializing new products, Codexis' ability to deploy its technology into market spaces adjacent to its pharmaceutical business and Codexis' customers receiving regulatory and market approval of their pharmaceutical products.

Source: Codexis, Inc.

### Codexis, Inc.

Investors

Paul Cox, 212-362-1200

[ir@codexis.com](mailto:ir@codexis.com)

or

Media

Jemma Connor, +44 161 359 3255

[jemma.connor@notchcommunications.co.uk](mailto:jemma.connor@notchcommunications.co.uk)